Sen. Durbin reintroduces Dietary Supplement Listing Act
He and other proponents of the listing, including FDA, assert that when Congress passed the Dietary Supplement Health and Education Act (DSHEA) of 1994, the absence of a provision require companies to register their products with FDA left the agency without the information needed to properly understand or oversee a market that has grown from $4 billion to more than $50 billion in sales over the last 30 years.
“There are more than one hundred thousand products on the market, but we don’t know critical information about most of them,” Sen. Durbin added. “Americans deserve a transparent supplement market, and it’s past time that we deliver it for them.”
The senator previously pushed for a mandatory product listing (MPL) in 2022 but legislative attempts ultimately failed to pass Congress.
If passed this time around, the legislation, would require companies to provide FDA with product names, a list of all ingredients, an electronic copy of the label; allergen statements health and structure/function claims and other information about their products. This information would be made public to Americans through an electronic database.
The statement from Sen. Durbin’s office highlighted that FDA received more than 2,000 adverse event reports related to dietary supplements in 2023 but that the agency estimated the actual annual number to be closer to 50,000 due to underreporting.
In a letter addressed to most of the dietary supplement trade associations in March, Sen. Durbin urged action against the inclusion of dangerous or illegal ingredients in products marketed as dietary supplements in the United States, such as tianeptine. He also previewed the reintroduction of his dietary supplement listing act. The trade associations replied that their members do not sell tianeptine and that the FDA should act to remove these illegal products from the market.
In its response to Sen. Durbin, the Natural Products Association(NPA) reiterated its continued objection to the legislation, noting that without additional considerations, reintroducing the previous legislation would continue to meet with opposition form NPA membership.
“NPA opposed this bill when you introduced it in 2022 as did the House and Senate committees of jurisdiction when they rejected it during consideration of the FDA user fee reauthorization bills,” wrote Daniel Fabricant, PhD, NPA president and CEO. “The narrative that the industry isn’t adequately regulated is false and should no longer be advanced as the basis for adding unnecessary regulations.”
In April, Sen. Durbin introduced the Prohibiting Tianeptine and Other Dangerous Products Act, which the trade associations warned was being used as a vehicle to reintroduce mandatory product listing and provide the FDA with new overreaching authorities.
“This bill, as written, would have the effect of denying access to legitimate dietary supplements to consumers,” Loren Israelsen, founder and president of the United Natural Products Alliance, previously told NutraIngredients. “While we oppose the language of this bill, we fully support FDA efforts to remove tianeptine from the market as an undeclared drug.”
What’s in the act
Source link
Share this article:












